<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01993667</url>
  </required_header>
  <id_info>
    <org_study_id>50402</org_study_id>
    <nct_id>NCT01993667</nct_id>
  </id_info>
  <brief_title>Acetazolamide for the Prevention of High Altitude Illness: a Comparison of Dosing</brief_title>
  <official_title>Acetazolamide for the Prevention of High Altitude Illness: a Comparison of Dosing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 4, randomized, double-blinded interventional trial comparing alternative
      doses of Acetazolamide for the prevention of High Altitude Illness.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acetazolamide, or Diamox, is the standard medical prophylaxis agent for high altitude
      illness. The medication is effective in preventing acute mountain sickness (AMS), high
      altitude pulmonary edema (HAPE), and high altitude cerebral edema (HACE). Its mechanism is
      via inhibition of the carbonic anhydrase enzyme which counteracts the respiratory alkalosis
      which occurs during ascent to altitude. It facilitates the excretion of bicarbonate in the
      urine. As a result, acetazolamide hastens acclimatization and helps prevent high altitude
      disorders.

      Current recommended dosing is 125 mg, orally twice daily, started 24 hours prior to ascending
      in elevation. Side effects include tingling of the fingers and toes and perioral numbness
      which may be erroneously interpreted as stroke symptoms. Since acetazolamide is a mild
      diuretic, frequent micturition may occur leading to interruption of daytime activities as
      well as broken sleep. These effects can affect safety at high altitude. Acetazolamide is
      normally discontinued 2 days after the user has reached their highest elevation or a plateau
      in elevation.

      A lower dose may be just as effective in preventing high altitude illnesses while preventing
      the disconcerting side effects resulting from its use. A smaller dose has not been studied,
      however. We will compare the common dose of 125 mg twice daily with a lower dose of 62.5 mg
      twice daily.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Acute Mountain Sickness as Measured by the Lake Louise Score</measure>
    <time_frame>12 days</time_frame>
    <description>Lake Louise Score, A total score of 3 to 5 indicates mild AMS. A score of 6 or more signifies severe AMS. Minimum value - 0, Maximum = 15</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Side Effects</measure>
    <time_frame>12 days</time_frame>
    <description>The typical side effects of acetazolamide will be measured daily (paresthesias of fingers and toes, change in urination frequency, and change in taste of beverages).
The side effect questionnaire included the following questions: In the past 12 h, have you experienced the following symptoms: Tingling of toes? Tingling of fingers? Increase in urination? Taste change of beverages? Symptoms were self-reported and rated on a 0-5 scale (0=none, 5=maximum)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>Prophylaxis of Acute Mountain Sickness</condition>
  <arm_group>
    <arm_group_label>Acetazolamide normal dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Experimental : Acetazolamide 125 mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acetazolamide low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: Acetazolamide 62.5 mg twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low Dose Acetazolamide</intervention_name>
    <description>Administration of low dose acetazolamide</description>
    <arm_group_label>Acetazolamide low dose</arm_group_label>
    <other_name>Diamox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Dose Acetazolamide</intervention_name>
    <description>Administration of normal dose acetazolamide</description>
    <arm_group_label>Acetazolamide normal dose</arm_group_label>
    <other_name>Diamox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years or older

          -  English or Indian speaking

          -  Mountaineers or trekkers who plan to climb Mt. McKinley or trek to Base Camp on Mt.
             Everest

        Exclusion Criteria:

          -  Low sodium and/potassium blood serum levels

          -  Kidney disease or dysfunction

          -  Liver disease, dysfunction, or cirrhosis

          -  Suprarenal gland failure or dysfunction

          -  Hyperchloremic acidosis

          -  Angle-closure glaucoma

          -  Taking high dose aspirin (over 325 mg/day)

          -  Any reaction to sulfa drugs or acetazolamide

          -  Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>McIntosh Scott, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Utah Health Sciences Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>November 12, 2013</study_first_submitted>
  <study_first_submitted_qc>November 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2013</study_first_posted>
  <results_first_submitted>November 26, 2018</results_first_submitted>
  <results_first_submitted_qc>January 10, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 29, 2019</results_first_posted>
  <last_update_submitted>January 10, 2019</last_update_submitted>
  <last_update_submitted_qc>January 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Scott McIntosh</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Altitude Sickness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetazolamide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Acetazolamide Normal Dose</title>
          <description>Experimental : Acetazolamide 125 mg twice daily
Acetazolamide: Administration of low dose acetazolamide</description>
        </group>
        <group group_id="P2">
          <title>Acetazolamide Low Dose</title>
          <description>Experimental: Acetazolamide 62.5 mg twice daily
Acetazolamide: Administration of low dose acetazolamide</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Insufficient data to analyze</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Insufficient altitude reached</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Acetazolamide Normal Dose</title>
          <description>Experimental : Acetazolamide 125 mg twice daily
Acetazolamide: Administration of low dose acetazolamide</description>
        </group>
        <group group_id="B2">
          <title>Acetazolamide Low Dose</title>
          <description>Experimental: Acetazolamide 62.5 mg twice daily
Acetazolamide: Administration of low dose acetazolamide</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="43"/>
            <count group_id="B2" value="47"/>
            <count group_id="B3" value="90"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.2" spread="12.7"/>
                    <measurement group_id="B2" value="41.6" spread="13.5"/>
                    <measurement group_id="B3" value="43.8" spread="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Acute Mountain Sickness as Measured by the Lake Louise Score</title>
        <description>Lake Louise Score, A total score of 3 to 5 indicates mild AMS. A score of 6 or more signifies severe AMS. Minimum value - 0, Maximum = 15</description>
        <time_frame>12 days</time_frame>
        <population>Seventy-three participants had sufficient data to be included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Acetazolamide Normal Dose</title>
            <description>Experimental : Acetazolamide 125 mg twice daily
Acetazolamide: Administration of low dose acetazolamide</description>
          </group>
          <group group_id="O2">
            <title>Acetazolamide Low Dose</title>
            <description>Experimental: Acetazolamide 62.5 mg twice daily
Acetazolamide: Administration of low dose acetazolamide</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Acute Mountain Sickness as Measured by the Lake Louise Score</title>
          <description>Lake Louise Score, A total score of 3 to 5 indicates mild AMS. A score of 6 or more signifies severe AMS. Minimum value - 0, Maximum = 15</description>
          <population>Seventy-three participants had sufficient data to be included in the analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Side Effects</title>
        <description>The typical side effects of acetazolamide will be measured daily (paresthesias of fingers and toes, change in urination frequency, and change in taste of beverages).
The side effect questionnaire included the following questions: In the past 12 h, have you experienced the following symptoms: Tingling of toes? Tingling of fingers? Increase in urination? Taste change of beverages? Symptoms were self-reported and rated on a 0-5 scale (0=none, 5=maximum)</description>
        <time_frame>12 days</time_frame>
        <population>These participants had sufficient data to be included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Acetazolamide Normal Dose</title>
            <description>Experimental : Acetazolamide 125 mg twice daily
Acetazolamide: Administration of low dose acetazolamide</description>
          </group>
          <group group_id="O2">
            <title>Acetazolamide Low Dose</title>
            <description>Experimental: Acetazolamide 62.5 mg twice daily
Acetazolamide: Administration of low dose acetazolamide</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Side Effects</title>
          <description>The typical side effects of acetazolamide will be measured daily (paresthesias of fingers and toes, change in urination frequency, and change in taste of beverages).
The side effect questionnaire included the following questions: In the past 12 h, have you experienced the following symptoms: Tingling of toes? Tingling of fingers? Increase in urination? Taste change of beverages? Symptoms were self-reported and rated on a 0-5 scale (0=none, 5=maximum)</description>
          <population>These participants had sufficient data to be included in the analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Acetazolamide Normal Dose</title>
          <description>Experimental : Acetazolamide 125 mg twice daily
Acetazolamide: Administration of low dose acetazolamide</description>
        </group>
        <group group_id="E2">
          <title>Acetazolamide Low Dose</title>
          <description>Experimental: Acetazolamide 62.5 mg twice daily
Acetazolamide: Administration of low dose acetazolamide</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Scott McIntosh, MD, MPH</name_or_title>
      <organization>University of Utah</organization>
      <phone>801-581-2730</phone>
      <email>Scott.McIntosh@hsc.utah.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

